Publikationen der Klinik für Urologie

Publikationen 2018

  1. Borgmann H, Salem J, Baunacke M, Boehm K, Groeben C, Schmid M, Siegel FP, Huber J (2018) Mapping the landscape of urology: A new media-based cross-sectional analysis of public versus academic interest. INT J UROL 25(5): 421-428, doi: 10.1111/iju.13527
  2. Bremmer F, Jarry H, Unterkircher V, Kaulfuss S, Burfeind P, Radzun HJ, Ströbel P, Thelen P (2018) Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. ONCOTARGET 9(24): 16951-16961, doi: 10.18632/oncotarget.24763
  3. Buergy D, Schneiberg V, Schaefer J, Welzel G, Trojan L, Bolenz C, Wenz F (2018) Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. HEALTH QUAL LIFE OUT 16(1): 21, doi: 10.1186/s12955-018-0844-8
  4. Groeben C, Koch R, Baunacke M, Schmid M, Borkowetz A, Wirth MP, Huber J (2018) Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014. ANN SURG ONCOL n.a.: n.a., doi: 10.1245/s10434-018-6381-1
  5. Hubert J, Weiser L, Hischke S, Uhlig A, Rolvien T, Schmidt T, Butscheidt SK, Püschel K, Lehmann W, Beil FT, Hawellek T (2018) Cartilage calcification of the ankle joint is associated with osteoarthritis in the general population. BMC MUSCULOSKEL DIS 19(1): 169, doi: 10.1186/s12891-018-2094-7
  6. Küffer S, Gutting T, Belharazem D, Sauer C, Michel MS, Marx A, Trojan L, Ströbel P (2018) Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation. MOL ONCOL 12(2): 256-266, doi: 10.1002/1878-0261.12164
  7. Martinschek A, Welzel G, Ritter M, Heinrich E, Bolenz C, Trojan L (2018) The concentration of console surgeons: prospective evaluation of the loss of attention in robotic-assisted procedures. J Robot Surg n.a.: n.a., doi: 10.1007/s11701-018-0800-y
  8. Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A, German Network Of Kidney Cancer (2018) High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. HUM PATHOL n.a.: n.a., doi: 10.1016/j.humpath.2018.08.006
  9. Seif Amir Hosseini A, Beham A, Uhlig J, Streit U, Uhlig A, Ellenrieder V, Joseph AA, Voit D, Frahm J, Uecker M, Lotz J, Biggemann L (2018) Intra- and interobserver variability in the diagnosis of GERD by real-time MRI. EUR J RADIOL 104: 14-19, doi: 10.1016/j.ejrad.2018.04.029
  10. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators (2018) Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. NEW ENGL J MED 378(15): 1408-1418, doi: 10.1056/NEJMoa1715546
  11. Soave A, Dahlem R, Pinnschmidt HO, Rink M, Langetepe J, Engel O, Kluth LA, Loechelt B, Reiss P, Ahyai SA, Fisch M (2018) Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity. EUR UROL 73(6): 910-922, doi: 10.1016/j.eururo.2017.11.014
  12. Tahbaz R, Schmid M, Merseburger AS (2018) Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. CURR OPIN UROL 28(1): 62-79, doi: 10.1097/MOU.0000000000000454
  13. Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV (2018) [The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer]. AKTUEL UROL n.a.: n.a., doi: 10.1055/s-0043-115426
  14. Uhlig A (2018) [Strategies to reduce patient loss during the follow-up period of randomized trials]. UROLOGE 57(5): 601-604, doi: 10.1007/s00120-018-0639-x
  15. Uhlig A, Behnes CL, Strauss A, Trojan L, Uhlig J, Leitsmann C (2018) Primary bladder adenocarcinoma: Case report with long-term follow-up. Urol Case Rep 18: 64-66, doi: 10.1016/j.eucr.2018.02.006
  16. Uhlig A, Hahn O, Strauss A, Lotz J, Trojan L, Müller-Wille R, Uhlig J (2018) Treatment for Localized T1a Clear Cell Renal Cell Carcinoma: Survival Benefit for Cryosurgery and Thermal Ablation Compared to Deferred Therapy. CARDIOVASC INTER RAD 41(2): 277-283, doi: 10.1007/s00270-017-1816-9
  17. Uhlig A, Mei J, Baik I, Meyer C, Uhlig J (2018) Screening utilization among cancer survivors: a meta-analysis. J Public Health (Oxf) 40(1): 129-137, doi: 10.1093/pubmed/fdx030
  18. Uhlig A, Seif Amir Hosseini A, Simon J, Lotz J, Trojan L, Schmid M, Uhlig J (2018) Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. J UROLOGY 200(1): 48-60, doi: 10.1016/j.juro.2017.11.150
  19. Uhlig J, Uhlig A, Kunze M, Beissbarth T, Fischer U, Lotz J, Wienbeck S (2018) Novel Breast Imaging and Machine Learning: Predicting Breast Lesion Malignancy at Cone-Beam CT Using Machine Learning Techniques. AM J ROENTGENOL 211(2): W123-W131, doi: 10.2214/AJR.17.19298
  20. Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM, Burger M, Protzel C, Hakenberg OW, von Landenberg N, Roghmann F, Noldus J, Nuhn P, Pycha A, Rink M, Chun FKH, May M, Fisch M, Aziz A, PROMETRICS 2011 Study Group (2018) Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. BJU INT 121(1): 101-110, doi: 10.1111/bju.14012

Publikationen 2017

  1. Dulz S, Asselborn NH, Dieckmann KP, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger LA, Alsdorf W, Mankichian B, Meyer C, Vetterlein MW, Gild P, Ludwig TA, Soave A, Schriefer P, Becker A, Ahyai SA, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun FKH, Kluth LA (2017) Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. J CANCER RES CLIN 143(7): 1319-1325, doi: 10.1007/s00432-017-2384-8
  2. Gehrig J, Kaulfuß S, Jarry H, Bremmer F, Stettner M, Burfeind P, Thelen P (2017) Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer. ONCOTARGET 8(21): 34971-34979, doi: 10.18632/oncotarget.16496
  3. Hijazi S, Echtle D, Aboumarzouk OM, Heinrich E (2017) Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension. Int J Womens Health 9: 625-630, doi: 10.2147/IJWH.S134239
  4. Kesch C, Radtke JP, Popeneciu IV, Gasch C, Dieffenbacher SC, Klein T, Schlemmer HP, Wieczorek K, Zogal P, Hohenfellner M, Sakas G, Hadaschik BA (2017) TOP: Prospective Evaluation of a Volume Based, Computer Assisted Method for Transperineal Optimized Prostate Biopsy. UROL INT 99(2): 149-155, doi: 10.1159/000458764
  5. Martinschek A, Stumm L, Ritter M, Heinrich E, Bolenz C, Trojan L (2017) Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy. UROL INT 99(2): 201-206, doi: 10.1159/000478027
  6. Naspro R, Gomez Sancha F, Manica M, Meneghini A, Ahyai S, Aho T, Fiori C, Vavassori I, DA Pozzo LF, Pansadoro V, Montorsi F, Herrmann TR (2017) From "gold standard" resection to reproducible "future standard" endoscopic enucleation of the prostate: what we know about anatomical enucleation. MINERVA UROL NEFROL 69(5): 446-458, doi: 10.23736/S0393-2249.17.02834-X
  7. Ohlmann CH, Thelen P (2017) [Antihormonal therapy in prostate cancer : Side effects]. UROLOGE 56(4): 465-471, doi: 10.1007/s00120-017-0340-5
  8. Rosenbaum CM, Reiss CP, Borgmann H, Salem J, Fisch M, Huber J, Schmid M, Ahyai SA (2017) Management of Anterior Urethral Strictures in Adults: A Survey of Contemporary Practice in Germany. UROL INT 99(1): 43-50, doi: 10.1159/000471928
  9. Salem J, Borgmann H, Baunacke M, Boehm K, Hanske J, Macneily A, Meyer C, Nestler T, Schmid M, Huber J (2017) Widespread use of internet, applications, and social media in the professional life of urology residents. CUAJ-CAN UROL ASSOC 11(9): E355-E366, doi: 10.5489/cuaj.4267
  10. Soave A, Dahlem R, Pinnschmidt HO, Rink M, Langetepe J, Engel O, Kluth LA, Loechelt B, Reiss P, Ahyai SA, Fisch M (2017) Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity. EUR UROL -: -, doi: 10.1016/j.eururo.2017.11.014
  11. Taubert H, Becker C, Füssel S, Seitz G, Thelen P, Wullich B (2017) [The 14th annual DPKK meeting on "Importance of molecular analysis for diagnosis and therapy"]. UROLOGE 56(6): 808-810, doi: 10.1007/s00120-017-0404-6
  12. Traceviciute J, Zwink N, Jenetzky E, Reutter H, Hirsch K, Stein R, Rösch WH, Ebert AK (2017) Sexual Function and Quality of Life in Adult Male Individuals with Exstrophy-Epispadias Complex-a Survey of the German CURE-Network. UROLOGY -: -, doi: 10.1016/j.urology.2017.08.063
  13. Tsaur I, Becker C, Thelen P, Roos FC (2017) [Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?]. UROLOGE 56(9): 1164-1167, doi: 10.1007/s00120-017-0461-x
  14. Uhlig A, Borkowetz A (2017) [Possibilities of rehabilitation programmes for adult cancer survivors]. UROLOGE 56(12): 1611-1614, doi: 10.1007/s00120-017-0537-7
  15. Uhlig A, Mei J, Baik I, Meyer C, Uhlig J (2017) Screening utilization among cancer survivors: a meta-analysis. J Public Health (Oxf) -: 1-9, doi: 10.1093/pubmed/fdx030
  16. Uhlig A, Strauss A, Seif Amir Hosseini A, Lotz J, Trojan L, Schmid M, Uhlig J (2017) Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus -: -, doi: 10.1016/j.euf.2017.08.007
  17. von Hardenberg J, Schwartz M, Werner T, Fuxius S, Strauss A, Worst TS, Nuhn P, Bolenz C, Heinrich E (2017) Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review. UROL INT 99(4): 414-421, doi: 10.1159/000477943
  18. von Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Frangenheim T, Bolenz C, Weiss C, Heinrich E (2017) Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel. ANTICANCER RES 37(9): 5117-5124, doi: 10.21873/anticanres.11931

Publikationen 2016

  1. Ahyai SA, Ludwig TA, Dahlem R, Soave A, Rosenbaum C, Chun FKH, Fisch M, Schmid M, Kluth LA (2016) Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence. BJU INT 118(4): 625-32, doi: 10.1111/bju.13449
  2. Hijazi S, Leitsmann C (2016) Clinical significance of video-urodynamic in female recurrent urinary tract infections. Int J Womens Health 8: 31-4, doi: 10.2147/IJWH.S94956
  3. Hijazi S, Echtle D, Hasselhof VM, Trojan L, Heinrich E (2016) Metal telescopic and Amplatz sheath dilation in nephrolithotomy. Urol Ann 8(1): 66-9, doi: 10.4103/0974-7796.163795
  4. Hijazi S, Meller B, Leitsmann C, Strauss A, Ritter C, Lotz J, Meller J, Trojan L, Sahlmann CO (2016) See the unseen: Mesorectal lymph node metastases in prostate cancer. PROSTATE 76(8): 776-80, doi: 10.1002/pros.23168
  5. Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C (2016) Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study. UROL INT 96(1): 57-64, doi: 10.1159/000433606
  6. Martinschek A, Pfalzgraf D, Rafail B, Ritter M, Heinrich E, Trojan L (2016) Transurethral versus suprapubic catheter at robot-assisted radical prostatectomy: a prospective randomized trial with 1-year follow-up. WORLD J UROL 34(3): 407-11, doi: 10.1007/s00345-015-1678-1
  7. Paffenholz P, Borgmann H, Nachite-Berges S, Borowitz R, Bründl J, Boehm K, Probst K, Schneidewind L, Schmid M, Salem J (2016) [Regional for Residents. GeSRU Programs at Regional Urology Meetings in Germany]. UROLOGE 55(4): 532-3, doi: 10.1007/s00120-016-0053-1
  8. Rosenbaum CM, Schmid M, Ludwig TA, Kluth LA, Dahlem R, Fisch M, Ahyai S (2016) Redo buccal mucosa graft urethroplasty: success rate, oral morbidity and functional outcomes. BJU INT 118(5): 797-803, doi: 10.1111/bju.13528
  9. Sahlmann CO, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, Trojan L, Meller J, Hijazi S (2016) Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. EUR J NUCL MED MOL I 43(5): 898-905, doi: 10.1007/s00259-015-3251-y
  10. Salem J, Borgmann H, MacNeily A, Boehm K, Schmid M, Groeben C, Baunacke M, Huber J (2016) New Media for Educating Urology Residents: An Interview Study in Canada and Germany. J Surg Educ epub: S1931-7204(16)30321-X, doi: 10.1016/j.jsurg.2016.11.009
  11. Taubert H, Becker C, Füssel S, Seitz G, Thelen P, Wullich B (2016) [Annual meeting of the German Prostate Cancer Consortium: Updates to circulating tumor cells, "liquid biopsy" and the role of the androgen receptor]. UROLOGE 55(5): 661-2, doi: 10.1007/s00120-016-0105-6
  12. Thelen P, Gschwend J, Wolff JM, Miller K (2016) [Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer]. AKTUEL UROL 47(1): 79-85, doi: 10.1055/s-0041-108295
  13. Waegner RH, Schmid M, Trojan L, Ahyai SA (2016) [Retroperitoneal endometriosis : When a rare form of endometriosis becomes a urological disease]. UROLOGE 55(6): 756-62, doi: 10.1007/s00120-016-0119-0

Publikationen 2015

  1. Bremmer F, Schallenberg S, Jarry H, Küffer S, Kaulfuss S, Burfeind P, Strauß A, Thelen P, Radzun HJ, Ströbel P, Honecker F, Behnes CL (2015) Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours. ONCOTARGET 6(32): 33426-37, doi: 10.18632/oncotarget.5288
  2. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO (2015) Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. PROSTATE 75(16): 1934-40, doi: 10.1002/pros.23091
  3. Klümper N, Syring I, Offermann A, Shaikhibrahim Z, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F (2015) Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. DIAGN PATHOL 10: 165, doi: 10.1186/s13000-015-0398-6
  4. Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3: 26, doi: 10.1186/s40425-015-0068-y
  5. Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, Meller J, Thelen P (2015) Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res 5(1): 66, doi: 10.1186/s13550-015-0145-8

Publikationen 2014

  1. Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Ströbel P, Radzun HJ (2014) Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. VIRCHOWS ARCH 464(2): 191-6, doi: 10.1007/s00428-013-1523-0
  2. Böttner M, Thelen P, Jarry H (2014) Estrogen receptor beta: tissue distribution and the still largely enigmatic physiological function. J STEROID BIOCHEM 139: 245-51, doi: 10.1016/j.jsbmb.2013.03.003
  3. Bremmer F, Jarry H, Strauß A, Behnes CL, Trojan L, Thelen P (2014) Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC). Springerplus 3: 574, doi: 10.1186/2193-1801-3-574
  4. Gierth M, Fritsche HM, Buchner H, May M, Aziz A, Otto W, Bolenz C, Trojan L, Hermann E, Tiemann A, Müller SC, Ellinger J, Brookman-May S, Stief CG, Tilki D, Nuhn P, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland WF, Riedmiller H, Denzinger S, Bastian PJ, Burger M (2014) Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. WORLD J UROL 32(2): 365-71, doi: 10.1007/s00345-013-1105-4
  5. Harke N, Schoen G, Schiefelbein F, Heinrich E (2014) Selective clamping under the usage of near-infrared fluorescence imaging with indocyanine green in robot-assisted partial nephrectomy: a single-surgeon matched-pair study. WORLD J UROL 32(5): 1259-65, doi: 10.1007/s00345-013-1202-4
  6. Thelen P, Wuttke W, Seidlová-Wuttke D (2014) Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J STEROID BIOCHEM 139: 290-3, doi: 10.1016/j.jsbmb.2013.06.009

Publikationen 2013

  1. Becker F, Junker K, Parr M, Hartmann A, Füssel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stöckle M, Jung V (2013) Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLOS ONE, 8(10): e78137.
  2. Behnes CL, Bedke J, Schneider S, Küffer S, Strauss A, Bremmer F, Ströbel P, Radzun HJ (2013) Myoglobin expression in renal cell carcinoma is regulated by hypoxia. EXP MOL PATHOL, 95(3): 307-12.
  3. Behnes CL, Schlegel C, Shoukier M, Magiera I, Henschke F, Schwarz A, Bremmer F, Loertzer H (2013) Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases. BMC UROL, 13: 3.
  4. Bolenz C, Auer M, Ströbel P, Heinzelbecker J, Schubert C, Trojan L (2013) The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value. UROL ONCOL-SEMIN ORI, 31(8): 1606-14.
  5. Buchner A, May M, Burger M, Bolenz C, Herrmann E, Fritsche HM, Ellinger J, Höfner T, Nuhn P, Gratzke C, Brookman-May S, Melchior S, Peter J, Moritz R, Tilki D, Gilfrich C, Roigas J, Zacharias M, Hohenfellner M, Haferkamp A, Trojan L, Wieland WF, Müller SC, Stief CG, Bastian PJ (2013) Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. EJSO-EUR J SURG ONC, 39(4): 372-9.
  6. Hasibeder A, Venkataramani V, Thelen P, Radzun HJ, Schweyer S (2013) Phytoestrogens regulate the proliferation and expression of stem cell factors in cell lines of malignant testicular germ cell tumors. INT JONCOL, 43(5): 1385-94.
  7. Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. EUR UROL, 63(6): 977-82.
  8. Heinzelbecker J, Katzmarzik M, Weiss C, Trojan L, Haecker A (2013) During twenty years of Cisplatinbased therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival. Int Braz J Urol, 39(1): 10-21.
  9. Heinzelbecker J, Kempf KM, Kurz K, Steidler A, Weiss C, Jackson DG, Bolenz C, Haecker A, Trojan L (2013) Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: correlation with pathologic parameters and clinical outcome. UROL ONCOL-SEMIN ORI, 31(7): 1386-94.
  10. Loertzer H, Schneider P (2013) [Stress incontinence in elderly women]. UROLOGE, 52(6): 813-20.
  11. Loertzer H, Strauß A, Ringert RH, Schneider P (2013) Laser-supported partial laparoscopic nephrectomy for renal cell carcinoma without ischaemia time. BMC UROL, 13: 31.
  12. Lumma PP, Schneider P, Strauss A, Plothe KD, Thelen P, Ringert RH, Loertzer H (2013) Impact of ureteral stenting prior to ureterorenoscopy on stone-free rates and complications. WORLD J UROL, 31(4): 855-9.
  13. May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W, Bolenz C, Gilfrich C, Trojan L, Herrmann E, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Wieland WF, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M (2013) Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. UROL ONCOL-SEMIN ORI, 31(7): 1141-7.
  14. Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A (2013) Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. PROSTATE, 73(15): 1699-709.
  15. Thelen P, Krahn L, Bremmer F, Strauss A, Brehm R, Loertzer H (2013) Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma. INT J MOL MED, 31(2): 339-46.
  16. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen J, Kaulfuss S (2013) Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. CARCINOGENESIS, 34(5): 1115-24.

Publikationen 2012

  1. Behnes CL, Hemmerlein B, Strauss A, Radzun HJ, Bremmer F (2012) N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma. DIAGN PATHOL, 7: 95.
  2. Bolenz C, Auer M, Ströbel P, Heinzelbecker J, Schubert C, Trojan L (2012) The lymphatic system in clinically localized urothelial carcinoma of the bladder: Morphologic characteristics and predictive value. UROL ONCOL-SEMIN ORI, x: x.
  3. Bremmer F, Thelen P, Pottek T, Behnes CL, Radzun HJ, Schweyer S (2012) Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis. ANTICANCER RES, 32(1): 341-9.
  4. Bremmer F, Hemmerlein B, Strauss A, Burfeind P, Thelen P, Radzun HJ, Behnes CL (2012) N-cadherin expression in malignant germ cell tumours of the testis. BMC Clin Pathol, 12(1): 19.
  5. Bremmer F, Kessel FJ, Behnes CL, Trojan L, Heinrich E (2012) Leiomyoma of the tunica albuginea, a case report of a rare tumour of the testis and review of the literature. DIAGN PATHOL, 7: 140.
  6. Gabriel U, Li L, Bolenz C, Steidler A, Kränzlin B, Saile M, Gretz N, Trojan L, Michel MS (2012) New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer. MOL CARCINOGEN, 51(11): 907-15.
  7. Heinzelbecker J, Gropp T, Weiss C, Huettl K, Stroebel P, Haecker A, Bolenz C, Trojan L (2012) The role of lymph vessel density and lymphangiogenesis in metastatic tumor spread of nonseminomatous testicular germ cell tumors. UROL ONCOL-SEMIN ORI, 11: 1078-1439.
  8. Herrmann MKA, Kertesz T, Gsänger T, Bloch E, Pollul G, Bouabdallaoui M, Strauss A, Herrmann M, Christiansen H, Wolff HA, Hess CF, Hille A (2012) Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study. RADIAT ONCOL, 7: 24.
  9. Loertzer H, Schneider P, Thelen P, Ringert RH, Strauß A (2012) [Laser now also to be used in organ-preserving kidney surgery?]. UROLOGE, 51(6): 837-42.
  10. Loertzer H, Schneider P, Thelen P, Ringert RH, Strauß A (2012) [Prolapse surgery. With abdominal or vaginal meshes?]. UROLOGE, 51(9): 1261-9.
  11. Martinschek A, Heinzelmann K, Ritter M, Heinrich E, Trojan L (2012) Radical prostatectomy after previous transurethral resection of the prostate: robot-assisted laparoscopic versus open radical prostatectomy in a matched-pair analysis. J ENDOUROL, 26(9): 1136-41.
  12. May M, Bastian PJ, Brookman-May S, Fritsche HM, Bolenz C, Gilfrich C, Otto W, Trojan L, Herrmann E, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M (2012) External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. J UROLOGY, 187(4): 1210-4.
  13. Nuhn P, May M, Fritsche HM, Buchner A, Brookman-May S, Bolenz C, Moritz R, Herrmann E, Burger M, Höfner T, Ellinger J, Tilki D, Roigas J, Zacharias M, Trojan L, Wülfing C, May F, Melchior S, Haferkamp A, Gilfrich C, Hohenfellner M, Wieland WF, Müller SC, Stief CG, Bastian PJ (2012) External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. EJSO-EUR J SURG ONC, 38(7): 637-42.
  14. Nuhn P, May M, Sun M, Fritsche HM, Brookman-May S, Buchner A, Bolenz C, Moritz R, Herrmann E, Burger M, Tilki D, Trojan L, Perrotte P, Haferkamp A, Hohenfellner M, Wieland WF, Müller SC, Karakiewicz PI, Bastian PJ (2012) External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. EUR UROL, 61(1): 58-64.
  15. Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ (2012) Novel options for the treatment of castration-resistant prostate cancer. WORLD J UROL, 30(4): 495-503.
  16. Otto W, May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Höfner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Müller SC, Kocot A, Riedmiller H, Wieland WF, Stief CG, Bastian PJ, Burger M (2012) Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. GENDER MED, 9(6): 481-9.
  17. Prado LG, Huber J, Huber CG, Mogler C, Ehrenheim J, Nyarangi-Dix J, Pahernik S, Hohenfellner M (2012) Penile methadone injection in suicidal intent: life-threatening and fatal for erectile function. J ANDROL, 33(5): 801-4.
  18. Schaefer IM, Seeliger S, Strauss A, Füzesi L, Ringert RH, Loertzer H (2012) A three-step technique for umbilicoplasty in a patent urachus. BJU INT, 109(4): 640-4.
  19. Schmitz-Dräger BJ, Lümmen G, Bismarck E, Fischer C, Mitglieder des Arbeitskreises Prävention Umwelt und Komplementärmedizin (PUK) der Deutschen Gesellschaft für Urologie e. V. (DGU) (2012) [Prevention of uro-oncological diseases]. UROLOGE, 51(5): 727-36.
  20. Stettner M, Krämer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, Thelen P (2012) Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. EUR J CANCER PREV, 21(1): 55-64.
  21. Thelen P, Ringert RH, Loertzer H, Strauß A (2012) [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?]. UROLOGE, 51(9): 1240-5.
  22. Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V (2012) Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. CAN J UROL, 19(3): 6261-7.
  23. Venkataramani V, Thiele K, Behnes CL, Wulf GG, Thelen P, Opitz L, Salinas-Riester G, Wirths O, Bayer TA, Schweyer S (2012) Amyloid precursor protein is a biomarker for transformed human pluripotent stem cells. AM J PATHOL, 180(4): 1636-52.

Folgen Sie uns